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Abstract: Bacterial biofilms are surface-attached communities of microorganisms that are 
protected by an extracellular matrix of biomolecules. In the biofilm state, bacteria are 
significantly more resistant to external assault, including attack by antibiotics. In their 
native environment, bacterial biofilms underpin costly biofouling that wreaks havoc on 
shipping, utilities, and offshore industry. Within a host environment, they are insensitive to 
antiseptics and basic host immune responses. It is estimated that up to 80% of all microbial 
infections are biofilm-based. Biofilm infections of indwelling medical devices are of 
particular concern, since once the device is colonized, infection is almost impossible to 
eliminate. Given the prominence of biofilms in infectious diseases, there is a notable   
effort towards developing small, synthetically available molecules that will modulate 
bacterial biofilm development and maintenance. Here, we highlight the development of 
small molecules that inhibit and/or disperse bacterial biofilms specifically through   
non-microbicidal mechanisms. Importantly, we discuss several sets of compounds derived 
from marine sponges that we are developing in our labs to address the persistent   
biofilm problem. We will discuss: discovery/synthesis of natural products and their   
analogues—including our marine sponge-derived compounds and initial adjuvant activity 
and toxicological screening of our novel anti-biofilm compounds. 
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1. Introduction 
Biofouling is a costly and destructive natural phenomenon that affects almost every economic 
sector from shipping to medicine, causing billions of dollars in damage and disruptions annually. 
While biofouling is typically linked to aquatic invertebrates, it is the formation of a biofilm that acts as 
the glue that binds these animals to a surface [1–3]. Biofilms can be generated by numerous species of 
microorganisms but are primarily the creation of bacterial microcolonies that have attached to a surface 
and shielded themselves in an extracellular matrix of polysaccharide, protein, and nucleic acids [3–6]. 
Utilizing this line of defense, bacteria have been able to successfully permeate every environmental 
niche, including the human body [5–9]. According to the NIH, biofilm-based microbial infections 
make up to 80% of all infections in human patients, leading the CDC to declare biofilms to be one of 
the most important medical hurdles of the century [7,10].  
In an effort to find viable sources of anti-biofilm agents, many researchers have started to extract 
and analyze natural products from a myriad of plants and marine organisms [11–13]. Many of these 
compounds are secondary metabolites that are generated by the host organism in response to external 
pressures, such as competition for space and potential predators [14–17]. In a marine environment, 
antimicrobial and antifouling metabolites are vital for many sessile organisms to insure that they do not 
host hazardous biofilms on their exposed surfaces, especially given that an overwhelming majority of 
the planet’s microbial biomass prefers to be in a biofilm state [6,18–20]. Of all the species studied, 
marine sponges (Phylum Porifera) have been some of the most valuable. Sponges have been the source 
of more than 30% of marine natural products, generating a diverse array of molecules that have been 
found to have not only antimicrobial capabilities but also have potential as cancer therapeutics [13,21]. 
Despite their potential, there are very few of these metabolites and their derivatives that can serve as 
biofilm modulators in a non-microbicidal manner. The purpose of this review is to present those 
compounds derived from sponges that have shown anti-biofilm potential without bactericidal effects, 
with particular focus on the screening and development of our own chemical libraries as an example. 
These non-lethal molecules are significant discoveries, because they have the potential to serve as 
therapeutic supplements that can enhance the efficiency of conventional antibiotics against biofilm-based 
infections without eliciting resistant phenotypes. While it is important to continue to expand our 
libraries of antibiotic molecules, it is essential for the continued efficacy of all antimicrobial drugs that 
new and effective adjuvants be discovered in order to mitigate the increasing microbial resistance 
derived from biofilms [7–9,18,22,23]. 
1.1. Biofilm Development and Defense 
Ever since van Leeuwenhoek noted his belief that the number of organisms found in 17th century 
dental plaque exceeded “the number of men in a kingdom”, biofilms have been a part of our 
understanding of how bacteria interact with their environment, but it was not until the late 20th century 
that we began to realize their true importance. Over the last few decades, intense study of a deluge of 
bacterial species from diverse environmental niches has lead to a generalized conception of how 
biofilms are formed [23,24]. For most species, biofilm formation occurs in five distinct stages (Figure 1) 
that are defined by a combination of phenotype and genetic changes [23]. Initially, planktonic bacteria Mar. Drugs 2011, 9  
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reversibly attach themselves to surfaces that they encounter and remain in this transient state until 
signaled by an environmental cue to form a less ephemeral relationship. Every species of bacteria has a 
specific set of environmental signals that will initiate biofilm formation. Many of these signals are the 
chemical messages used for intercellular signaling within a population to coordinate altered gene 
expression in response to population density, a phenomenon known as quorum sensing [25–28]. It is 
also during the first stage of attachment that most antifouling and antimicrobial compounds are the 
most effective, because the bacteria have not coated themselves in the exopolymeric substance (EPS) 
and are in a vulnerable state. 
Figure 1. Biofilm maturation cycle. 
 
Once the bacteria begin to secrete EPS, biofilm development has progressed to its second stage and 
has become an irreversible process. The EPS is a complex, highly polar mixture of biomolecular 
materials that provides the resident bacteria with protection against bactericidal compounds and host 
immune responses [29]. EPS secretion continues throughout the third stage of formation, securely 
attached the bacteria to the surface within a thick, complex layer of biomolecules [30]. As the biofilm 
reaches maturity, it will take on a three-dimensional tower structure. Within these towers, small 
transport channels form, which facilitate the distribution of nutrients, water, and waste and carry 
planktonic bacteria to be housed in small cavities. In addition to logistical functions, the morphology 
of a biofilm lends itself as an ideal environment for hypermutation and increased gene transfer, which 
lead to higher rates of resistance [19,31–33]. Further exacerbating the resistance problem, bacterial 
metabolic activity within a biofilm is not uniform and highly dependent on the internal location of the 
bacterium, making the cell more able to withstand microbicides (Figure 2) [34–36]. Finally, once the 
biofilm reaches full maturity, sections of the tower begin to detach either by erosion (small loses) or by 
sloughing (large portions), and those cavities of free-floating bacteria are emptied, releasing fresh 
bacteria into the environment [37,38].  Mar. Drugs 2011, 9  
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Figure 2. Various levels of defense provided by biofilms. 
 
While physical characteristics of biofilm morphology contribute to the significant difference 
between planktonic and biofilm antibiotic resistance, no one has been able to discern a shared means of 
resistance for all species. One way of better defining this problem is the prevailing persistor cell 
theory. According to this theory, each biofilm contains a small population of highly resistant bacteria 
that are able to survive antibiotic kill-off to rebuild the biofilm population [39–41]. Although the 
concept of persistor cells has been around over seventy years, it has only been through the recent 
increase in medical biofilm research that the correlation between biofilm-based disease relapse models 
and persistor cells could have been made [42]. Since the persistor cells are protected, they are able to 
reproduce once the microbicidal insult abates and yield stronger progeny that have a significantly 
higher chance of being antibiotic resistant after each treatment, leading to a chronic disease that is 
driven by antibiotic resistant bacteria found in normal acute infections.  
1.2. Biofilm Importance in Industry and Medicine 
Over the last century, biofilm research has been primarily focused on their adverse role in industrial 
biofouling. Biofouling is the term used to describe the unwanted formation of microbial stratum or 
deposits of their waste products on a submerged surface [43]. The effects of biofouling can be felt across 
numerous industries and is a particular costly problem in food processing, utilities and marine-based 
industries. For most of the industrial victims, biofilm costs are directly related to a decrease in their 
production efficiency through energy losses, physical deterioration, and chemical interference [4,43–45]. 
A long-standing problem for naval and merchant ships has been the increased hydrodynamic drag and 
decreased maneuverability that is caused by biofouling of ship hulls, which increases fuel consumption 
and voyage costs [44]. Another costly result of biofouling is the long-term damage that results from the 
biocorrosion of equipment and other metal surfaces. Biocorrosion is a synergistic phenomenon that 
results from the combination of natural abiotic corrosion and biofilm-generated corrosive metabolites 
and waste products [4]. In an attempt to reduce the financial losses, many different antifouling Mar. Drugs 2011, 9  
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strategies have been developed, especially for seafaring ships. Most of these antifouling techniques 
consist of coating the submerged surface with a chemically enhanced paint that prevents the successful 
attachment of fouling organisms [44]. Unfortunately, the most successful coatings relied on toxic 
heavy metals or organotins (tributyltin or TBT) that were banned due to their mutagenic effects and 
bioaccumulation in many marine animals [44,46–49]. Other antifouling methods have looked to use 
biocides or low energy polymers. Neither of these methods have been as successful as TBT at 
controlling fouling, and several of the “booster biocides” have been found to accumulate in marine 
environments [44,49]. While many marine natural products have proven to be good non-toxic 
antifouling agents, they are difficult to generate for large-scale uses, such as antifouling coatings. A 
promising solution to this production problem is the creation of antifouling agents that are biomimetic 
compounds or compounds that are synthetic in nature but inspired by natural products, many of which 
have been derived from marine sponge metabolites [50]. 
More recently, bacterial biofilms have been linked to a wide range of chronic ailments and are 
believed to be the principle culprits involved in persistent nosocomial infections that develop in 
immune-compromised patients [7,51,52]. By definition, biofilms provide their inhabitants with 
protection against many of the environmental and chemical threats that would normally destroy their 
planktonic brethren including many of the antiseptics and anti-microbial agents used to sterilize 
hospital facilities. This level of protection is also extended to protect invading bacteria against the 
host’s immune defenses and has been shown to increase bacterial resistance to conventional antibiotics 
by nearly 1000-fold [53–55].  
Some of the worse cases of persistent biofilm-based infections occur when a patient receives an 
infected indwelling medical device (IMD), such as a catheter [56–58]. In many of these cases, the 
infection cannot be overcome without additional surgery to clean out the effected area and replace the 
tainted device with a new one [59]. Just as with biofouling in industry, medical research has looked to 
antifouling coatings to counter IMD infections. A wide range of antibiotic (e.g., cefazolin and 
rifampin/minocycline) and chemical compounds (e.g., salicylic acid and silver/chlorohexidine) have 
been tested as potential coatings, but many of these compounds have an inherent risk of causing 
resistance phenotypes to develop [56,60–67]. Despite significant advances in anti-microbial research in 
the last fifty years, there have only been two major antibiotic discoveries, oxazolidinones and 
lipopeptides [68,69]. Further exasperating this problem, these new classes of antibiotics are only active 
against Gram-positive infections. Therefore, the pursuit of compounds that have the ability to modulate 
biofilm formation has become a major goal for therapeutic research in order to overcome MDR 
infections [9]. 
2. Anti-Biofilm Agents Derived from Marine Sponges 
Marine sponges can be likened to little factories for bioactive secondary metabolites. These benthic 
organisms are some of the simplest multicellular animals with little differentiation and long lives, relying 
on the water around them to supply all their essential needs. Therefore, the generation of chemical 
defenses is a key element of their survival [70], whether they need to ward off predators [71–73], fight 
off competition for space and resources [74–76] or control surface fouling [48,73]. Sponges utilize a 
plethora of chemical classes to protect themselves and even to communicate with symbiotic organisms Mar. Drugs 2011, 9  
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that can provide nutrients and additional protection [77]. Many of these chemicals have been found  
to have antifouling and anti-biofilm properties, but very few have been shown to modulate   
biofilm formation without killing the bacteria or disrupting their growth. To date, only two classes of 
marine sponge metabolites house non-bactericidal biofilm modulators, the terpenoids [78,79] and the 
pyrrole-imidazoles [80–83].  
Although not unique to sponges, one of the most potent and diverse groups of molecules is the 
terpenes and their derivatives. Terpenes have a high degree of structural diversity stemming from the 
modification of isoprene subunits and are valued for their broad range of biological activity, from 
antifouling agents to antiproliferative cancer therapeutics [16,84,85]. Within the sponge terpenoids, 
only ageloxime-D, manoalide, and two manoalide congeners have been reported to have the ability to 
infer with bacterial biofilm formation without disrupting cellular growth [78,79].  
In addition to the use of terpenoids, marine sponges are capable of synthesizing a class of potent 
molecules that is completely unique to their phylum, the pyrrole-imidazole alkaloids (PIA) [86]. PIAs 
have been extracted from several families of sponges with extensive focus of the bromopyrrole 
derivatives from the Agelasidae family [72,87,88]. As natural products, the PIAs, especially oroidin 1, 
sceptrin 2, and bromoageliferin 3 (Figure 3), have been found to be potent and toxic antifouling agents, 
working against microorganisms and higher organisms alike [72,86,87,89]. Yet, from these molecules, 
the Melander group has been able to construct a series of very successful anti-biofilm libraries that 
utilize the 2-aminoimidazole moiety found within many of the PIAs [49,80,83,86,90–93]. 
Figure 3. Potent antifouling pyrrole-imidazole alkaloid natural products: oroidin (1), 
sceptrin (2), and bromoageliferin (3). 
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2.1. Ageloxime-D 
The sponge genus Agelas  (Agelasidae) was initially investigated in the mid-1990s because of   
the potent anti-predatory effects of its bromopyrrole metabolites [71–73,94], but it is now the source  
of numerous compounds that have immense pharmacologically potential, such as anticancer,   
antiviral, anti-biofilm, and antibiotic activities [87,95–99]. One class of compounds that has emerged 
as a unique and potent Agelas metabolite is the agelasine class, a diterpenoid [100]. Agelasines can be 
structurally defined as quaternary adenine salts composed of cyclic diterpene and a 9-methyladeninium 
moiety [101,102]. Currently, there are at least 12 agelasine derivatives [78,85], and of all these 
molecules, only one has been shown to have anti-biofilm capabilities without having a bactericidal 
effect (Figure 4). Last year, T. Hertiani and co-workers reported that the diterpenoid metabolite,   
(−)-ageloxime-D  4, was able to inhibit Staphylococcus epidermidis biofilm formation without 
inhibiting bacterial growth, while its parent molecule, (−)-agelasine-D 5, had the exact opposite effect. 
In addition to its potential as a biofilm modulator, the oxime, despite only varying from 5 at C-6′, was 
shown to retain most of its anticancer properties and to have a 10× increase in its antimacrofouling 
activity [49,78].  
Figure 4. (−)-Ageloxime-D (4) and (−)-Agelasine-D (5). 
 
2.2. Manoalides 
Another set of terpenoid compounds that has shown potential as biofilm modulators are also some 
of the most extensively studied marine sponge metabolites, the manoalides. First identified by Schuler 
in the early 1980s, manoalide 6 (Figure 5) is a sesterterpenoid from Luffariella variabilis with 
antibiotic and anti-inflammatory abilities [84]. Manoalide acts to block inflammation by irreversibly 
binding with phospholipase A2, an enzyme responsible for converting phospholipids into eicosanoid 
substrates [103–108]. Shortly after identifying manoalide, Schuler discovered three additional 
derivatives, secomanoalide 7, (E)-neomanoalide 8, and (Z)-neomanoalide 9 (Figure 5). These derivative 
compounds and their parent molecule were tested for antibiotic activity and found to be effective against 
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Gram-positive bacteria only [84,109]. In 2007, Skindersoe and co-workers determined that extracts from 
L. variabilis were effective quorum sensing inhibitors (QSI) against both Gram-positive and   
Gram-negative species [79]. QSIs are molecules that are able to prevent bacterial attachment and 
biofilm formation by jamming intercellular communication amongst the bacteria. Knowing that 
manoalides were the major metabolites for L. variabilis [110], Skindersoe looked at the QSI activity of 
manoalide, secomanoalide, and manoalide monoacetate 10 (Figure 5) individually and confirmed that 
all three compounds were QSIs for both groups of bacteria, attributing the activity to the conserved 
2(5H)-furanone substituent [79]. While manoalides are Gram-positive bactericides, the combination of 
the ineffectiveness against Gram-negative bacteria and their role as QSIs provide a strong source for 
future biofilm modulators, especially against life-threating infections by Gram-negative pathogens 
(e.g., Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumonaie).  
Figure 5. Manolide (6), Secomanoalide (7), Neomanoalide (E (8), Z (9)), and Manoalide 
Monoacetate (10). 
 
2.3. Pyrrole-Imidazole Alkaloids 
While many classes of natural products are shared across multiple species, the pyrrole-imidazole 
alkaloids have been found exclusively in marine sponges and serve as the major defense metabolites 
for  Agelasidae, Dyctionellidae, Hymeniacidonidae, and Axinellidae species [71–73,88,94,111]. In 
R = H, Manoalide (6) 
R = Ac, Manoalide monoacetate (10) 
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nature, the sessile sponges use these potent molecules as antifeedant defense mechanisms against 
predatory fish [71,72,88,112,113]. Subsequent investigation into the anti-attachment activity of the 
PIAs has shown that bromoageliferin and its parent molecule, oroidin, were able to interfere with 
bacterial attachment of Rhodospirillum salexigens and Vibrio vulnificus [89,114], but there has been 
limited research into the anti-biofilm capabilities of other PIAs. This class of molecule can range in 
complexity from a simple linear oroidin to the 16-stereocenter stylissadines 11 and 12 (Figure 6) [86]. 
Within the PIAs, oroidin, clathrodin 13, and hymenidin 14 (Figure 6) are believed to be the basic 
biosynthetic units for the construction of the larger and more complex congeners, such as konbu’acidin 
15 and the axinellamines 16 (Figure 7) [115,116], but one structural feature that is conserved across 
almost all of the nitrogen-rich PIAs is the presence of the 2-aminoimidazole (2-AI) moiety [111]. 
Figure 6. Agelas  pyrrole-imidazole alkaloids range in complexity from simple oroidin 
variants (13, 14) to the stylissadines (11 and 12). 
 
Clathrodin, R1 = R2 = H (13) 
Hymenidin, R1 = H, R2 = Br (14) 
Stylissadine A, R = β–H2′ (11) 
Stylissadine B, R = α–H2′ (12) Mar. Drugs 2011, 9  
 
 
2019
Figure 7. Konbu’acidin (15) and Axinellamine (16).  
 
Within most natural product classes, there exists key structural elements or pharmacophores   
that provide the molecule with its bioactivity and that can be used as the scaffolding for the 
development of small molecule libraries that can be synthesized in high product yields for further 
investigation. It was hypothesized that the highly conserved 2-AI groups were principal components of 
PIA anti-biofilm activity, leading to the development of two bromoageliferin derivatives, TAGE 17 
(trans-bromoageliferin) and CAGE 18 (cis-bromoageliferin) (Figure 8). These 2-AI compounds were 
assessed for anti-biofilm activity against Pseudomonas aeruginosa PAO1 and PA14 biofilms using 
crystal violet assays and were found to inhibit biofilm formation in a dose-dependent manner (PAO1 
IC50: 100 μM (TAGE and CAGE); PA14 IC50: 190 μM (TAGE) and 180 μM (CAGE)) without 
demonstrating a bactericidal effect on growth [80]. In addition to inhibiting biofilm formation, TAGE 
was further able to disperse pre-existing P. aeruginosa biofilms with PAO1 EC50 of 82 μM and a 
PA14 EC50 of 114 μM [117]. Here, IC50 is defined as the concentration required to inhibit 50% biofilm 
formation; while, EC50 is defined as the concentration required to disperse 50% of a preformed biofilm.  
Figure 8. trans-bromoageliferin (TAGE) (17) and cis-bromoageliferin (CAGE) (18). 
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To support TAGE’s role as a non-microbicidal biofilm modulator, the phenotypic effects of the 
molecule were visualized using fluorescence-based experiments with confocal laser scanning 
microscopy (CLSM) and flow cytometry. One CLSM experiment demonstrated that 100 μM TAGE 
directly affected the biofilm architecture of static P. aeruginosa PAO1 when compared to untreated 
cultures due to a large decrease in biomass, and the addition of cellular viability staining confirmed 
that there was not a significant effect on the ratio of living to dead cells in the presence of TAGE. The 
next fluorescence experiment used flow condition analysis of PAO1:GFP biofilms to validate the 
crystal violet assays and resulted in a significant decrease in the fluorescence signal in the TAGE 
samples versus the untreated media [117]. Following the success of the 2-AI variants, the next step 
was to enhance the anti-biofilm properties of TAGE through addition of other important PIA structural 
motifs. This next generation of bromoageliferin-derived compounds extended the simple structure of 
TAGE with the addition of brominated acylpyrroles. Three brominated analogues were synthesized, 
di-brominated 19, des-brominated 20, and mono-brominated 21 (Figure 9) and tested for anti-biofilm 
activity against six γ-proteobacteria species. As the level of bromination increased, the biofilm 
inhibition activity also increased in comparison to the TAGE scaffold, but the lacked TAGE’s potency 
against preformed biofilms [117]. 
Figure 9. Brominated analogues of TAGE. 
 
In the wake of the TAGE triumphs, the 2-AI project was expanded to assess the anti-biofilm 
efficacy of simpler structures derived from PIAs. The first step was to better analyze the bioactivity  
of oroidin, the fundamental building block of most PIAs. Following the same assay method used to  
test the bromoageliferin derivatives, oroidin was found to have very similar biofilm IC50 values   
against PAO1 and PA14 to those of TAGE and CAGE [82,118]. As an added bonus, the results of the 
oroidin assays supported the previous R. salexigens findings and showed that 2-AI activity could   
have interspecies activity in addition to confirming that the simpler oroidin structure could be used as  
a modulator scaffold. Therefore, a small chemical library was developed in order to study the 
structure-activity-relationships (SAR) of oroidin-based analogues as they pertain to anti-biofilm 
behavior [82,91]. Analogues were designed based on the systematic variation of three regions of the 
oroidin molecule: the tail, linker, and head groups (Figure 10). 
19: R1 = R2 = Br 
20: R1 = R2 = H 
21: R1 = H, R2 = Br Mar. Drugs 2011, 9  
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Figure 10. Structure-activity relationship (SAR) design regions for oroidin derivative library. 
 
In order to identify the essential structural components for anti-biofilm activity, each modification 
in the library was evaluated against the PAO1 and PA14 strains. Head group modifications consisted 
of 2-AI, 2-amino-4-oxoimidazole, imidazole, tryptophan, 2-thioimidazolone, and 2-aminothiazole; 
while, the tail group was removed or exchanged for a NH pyrrole or N-methyl pyrrole with varied 
degrees of halogenation. The linker region was evaluated based on variation of saturation and aliphatic 
length, either being truncated or extended by one carbon prior to the amide. While many of these 
modifications could inhibit biofilm formation, the most potent analogue turned out to be a variant of 
another known PIA, sventrin. This sventrin congener, known as dihydrosventrin (DHS) 22 (Figure 11), 
was found to have biofilm inhibition and biofilm dispersion dose-dependent activity against 
Acinetobacter baumannii, different strains of P. aeruginosa, and Bordetella bronchiseptica RB50 
without any microbicidal activity [91]. The SAR studies also provided insight into the importance of 
the 2-AI head group and which tail group modifications contributed the best anti-biofilm 
enhancements. The loss of the 2-AI head group on the oroidin derivatives completely destroyed their 
modulating ability, and as shown by the success of DHS, the best tail groups were those that contained 
dibromonated N-methyl pyrrole moieties. 
Figure 11. Dihydrosventrin (DHS).  
 
Armed with the results of the first SAR studies, a second library was developed that targeted the 
acylation of the pyrrole tail. For this round of analogues, the N-heteroaryl position was modified to 
increase steric bulk, and the importance of the bromopyrrole tail group was further explored using 
single atom modifications (Figure 12). The N-heteroaryl modifications yielded six new and potent 
biofilm modulators that showed better inhibition and dispersion against A. baumannii than their parent 
molecule, DHS. The best agent was the p-bromophenyl addition 23 (Figure 12), which was determined 
to lack any antibiotic activity. Additional SAR modifications were made to 23 in order to further assess 
the importance of tail halogenation with the removal of both pyrrole bromines, leaving only the 
halogenated phenyl group. Without a halogenated pyrrole, the molecule lost a significant amount of its 
   
Region C 
(head) 
Region B 
(linker) 
Region A 
(tail) 
22 Mar. Drugs 2011, 9  
 
 
2022
A. baumannii anti-biofilm capabilities. In conjunction with halogen SAR studies, the tail ring of DHS 
was resynthesized with a single atom modification that converted the pyrrole into an imidazole moiety 
24 (Figure 12), which caused a drastic drop in activity and reinforced the importance of the 
dibromonated pyrrole in the tail [91]. 
Figure 12. The most (23) and least (24) successful modifications from the second-generation 
oroidin SAR. 
 
While the initial SAR studies of the oroidin analogues provided a detailed understanding of the 
structural requirements to elicit biofilm modulation activity, the synthetic methods utilized to construct 
the libraries severely limited the chemical flexibility needed to further compound development. 
Therefore, two new libraries were devised that focused on the use of alternate connections between the 
2-AI head group and the acylpyrrole tail. The first of these chemical libraries stemmed from a reversal 
of the natural orientation of the amide bond connecting the two portions of the molecule and allowed 
for more diverse tail group exchange using a variety of commercial amines [119]. Dubbed the “reverse 
amide” or RA library, only the aliphatic analogues (25–28) (Figure 13) were found to be viable 
candidates with biofilm inhibition activity that was four times better than oroidin, and the biofilm 
inhibition assays showed that the bioactivity of this group was directly related to the length of the 
aliphatic chain attached to the compound. As the length of the chain increased by five carbons to 
eleven carbons, the IC50 values against P. aeruginosa (already in the low µM range) dropped by nearly 
20 fold (Figure 13). Additionally, the most active RA molecule, 28, was found to be a very potent 
preformed biofilm dispersal agent [119]. To gain better insight into how the length of the aliphatic 
chain affects anti-biofilm activity, the RA library was expanded to include analogues with up to   
18 carbons. When assayed against P. aeruginosa PA14, a threshold was determined at a chain length 
of 13 carbons, 29, with an IC50 value of 729 nM. Beyond that length, the inhibition activity began to 
drastically decrease [90]. Additional RA modifications that were assessed in the expanded library 
included altering the location of the amide linkage along the chain, including additional aliphatic 
chains and the incorporation of a triazole isostere. After assaying these analogues against PA14 and  
A. baumannii, it was evident that the amide bond was not a vital structural element for biofilm activity, 
but some of these modifications did enhance the molecule’s activity [90]. 
23 
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Figure 13. SAR study of the reverse amide tail groups. 
 
The second 2-AI library that was developed looked to increase the range of available analogues by 
utilizing the compatibility of the click reaction with a diverse array of substrates to replace the pyrrole 
tail group. A library of 2-aminoimidazole/triazole (2-AIT) compounds was generated through a click 
reaction involving an unprotected 2-AI alkyne species with varying linker lengths and an azide bearing 
the tail group of interest (Figure 14) [93]. From the initial biofilm activity screens against P. aeruginosa, 
A. baumannii, and B. bronchiseptica RB50, a single active agent was discovered that possessed a 
substituted unsaturated aryl group. Retaining the aryl pendant group, additional analogues were 
synthesized that examined the effects of extending the 2-AI linker region. This round of assays yielded 
one of the most potent anti-biofilm compounds to date, 30 (Figure 14). Possessing strong inhibitory and 
dispersal capabilities across all assayed Gram-positive and Gram-negative bacterial species without any 
antimicrobial activity, 30 established a highly successful template for further 2-AIT derivations [93]. The 
current research into the anti-biofilm properties of the 2-AI analogues has shown that, not only is the 
oroidin class a member of a select group of natural products with the ability to modulate biofilm 
formation, but it also directly affects the biofilm phenotype across multiple species without antibacterial 
or antimicrobial activity that could lead to the development of resistance phenotypes. 
Figure 14. Representation of the “click” reaction used to generate the 2-aminoimidazole/ 
triazole lead analogue, SPAR. 
 
25: n = 5 
26: n = 7 
27: n = 9 
28: n = 11 
29: n = 12 
30Mar. Drugs 2011, 9  
 
 
2024
3. Anti-Biofilm Agents Clinical and Industrial Status 
Therapeutic interest in sponge metabolites has been active since Bergmann’s research during the 
early twentieth century lead to the development of antileukemia drug ara-C [120,121]. Over the decades, 
marine sponges have yielded a diverse array of molecules that have been linked to anti-inflammatory, 
antitumor, antiviral, antiprotozoal, and antibiotic activities [13,122]. Now, sponges have become a 
source of non-microbicidal biofilm modulators that could help rescue the medical field from the 
increasing threat of MDR infections. To date, very little research has furthered the anti-biofilm 
applications of the terpene compounds, ageloxime-D or the manoalides, but extensive pre-clinical 
studies have been performed on the 2-aminoimidazole libraries.  
The native toxicity of the PIAs serves as a potent defense mechanism for sponges, and it also acts as 
a major hurdle that must be overcome before these compounds can be used from medical treatment. 
The MTT evaluation of the first generation of bromoageliferin derivatives, TAGE and CAGE, against 
GH4C1 rat pituitary and N2A mouse neuroblastoma cell lines showed that the 2-AI analogues lacked 
the mammalian cytotoxicity of their parent molecule [117,123]. Subsequent toxicological screens of 
the RA and 2-AIT libraries using Caenorhabditis elegans further supported the negligible toxicity of 
these compounds with minimal exposure thresholds of nearly 800 µM or higher in many cases five to 
ten times greater than the compound’s inhibition concentrations (Figure 15) [92].  
Figure 15. Example of C. elegans toxicity assay used to assess the RA and   
2-aminoimidazole/triazole (2-AIT) lead compounds [92]. 
 
While the broad spectrum and potent anti-biofilm properties of the 2-AI molecules are enough to 
merit further study, recent work with the lead 2-AIT, SPAR, has shown the promise of these molecules 
as adjuvants for conventional antibiotic therapy [83]. When combined with conventional antibiotics, 
the 2-AIT conjugate has proven to be able to resensitize previously resistant bacterial strains to   
the antibiotic, allowing the drug to resume its activity. In particular, this compound was able to Mar. Drugs 2011, 9  
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resensitize drug-resistant methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant 
Acinetobacter baumannii (MDRAB), both extremely dangerous causative agents of nosocomial 
infections, to many of the antibiotics used to treat their non-resistant counterparts, such as penicillin G, 
tetracycline, and imipenem (Figure 16) [83].  
Figure 16. Adjuvant activity assay with the lead 2-AIT, SPAR (30), and tobramycin 
against Pseudomonas aeruginosa PDO300. Shows that tobramycin and 2-AIT alone are 
not effective against PDO300, but combined the 2-AIT makes PDO300 more susceptible to 
tobramycin [83].  
 
 
In addition to a plethora of pharmacological applications, marine sponge metabolites have been 
actively pursued for their antifouling applications [43,44,49]. Many of the terpene and pyrrole-imidazole 
alkaloids have proven to have antifouling capabilities against both microfouling and macrofouling 
organisms, but many of these compounds are either toxic or have limited industrial applications due to 
formulation difficulties. Of the biofilm modulators reported in this review, the only compound that has 
been tested directly for marine antifouling activity has been the oroidin analogue, dihydrooroidin 
(DHO) 31 (Figure 17). DHO is an easily synthesized oroidin variant [118] that was an active inhibitor 
of biofilm formation against the bacterial fouling agent, Halomonas pacifica. Based on its success 
against H. pacifica, DHO was combined with marine-based paint and subjected to mesocosm tank 
trials. After three weeks in the tanks, the DHO paint had 125% less biomass than the paint-only 
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controls. These trials showed that DHO was a viable antifouling agent and was still active after three 
weeks in the tank. Since PIAs are notorious toxins, DHO toxicity was evaluated using the same 
mammalian cytotoxicity assays used to evaluate TAGE and was found to be nontoxic up to six times 
the dosage used in the paint trials [81,117]. The combination of their medicinal and antifouling 
applications have proven the power and far-reaching potential of the 2-aminoimidazole compounds to 
help overcome many of the complications caused by biofilm-forming bacteria. 
Figure 17. Dihydrooroidin (DHO). 
 
4. Future Perspectives 
As we advance our knowledge of how to design potent anti-biofilm molecules, a few issues have 
become clear. First, we need to understand the basic mechanistic aspects of how these molecules exert 
their activity. These molecules have the ability to provide tools to deconvolute bacterial signaling 
pathways that are both conserved and unique to Gram-positive and Gram-negative bacteria. Second, 
these compounds need to be evaluated in various animal models of infection. As a therapeutic strategy, 
these compounds will mostly likely serve as adjuvants to conventional antibiotics, and there are dosing 
and pharmacokinetic/pharmacodynamic (PK/PD) issues that must be optimized between the antibiotic 
and anti-biofilm agent. Third, new molecular classes should be investigated to expand our repertoire of 
anti-biofilm agents. To this end, we recently started to investigate the flustramine family of natural 
products to probe indole signaling, a pathway proposed along with quorum sensing AI-2 to be a 
universal interspecies signal [124–126]. Fourth, now that we have potent anti-biofilm molecules, the 
various in vitro biofilm assays need to be compared to in vivo outcomes.  
Finally, further toxicity tests need to be established, especially with regards to the effects of   
anti-biofilm compounds on commensal bacteria in their native host (such as gut bacteria). Before 
advancing to costly animal models, it has been shown that simple nematode models are a good source 
of preliminary toxicological analysis, providing a high-throughput platform for evaluating cytotoxicity 
and host neurological, developmental, and immune dose-responses [127–133]. Major advantages of 
using  C. elegans for toxicity studies include its completed genome, short lifespan, and simple 
physiology and have lead to the development of rapid assays that can measure dosage effects on   
gene expression and aid in determining sublethal dosages using a variety of indicators, such as 
RNA/DNA [128,134–137]. As a preliminary “curing” study, the use of C. elegans offers a simple, 
high-throughput method for evaluating the activity of these compounds against an active infection, 
providing insight into both host and pathogen in vivo dose responses [135,137–139]. 
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